ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder Read more about ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients Read more about Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
FPA150 in Patients With Advanced Solid Tumors Read more about FPA150 in Patients With Advanced Solid Tumors
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC Read more about A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer Read more about Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Read more about Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors Read more about A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a Read more about Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Read more about Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC Read more about Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC